Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss

A legfontosabb adatok

Ki végzi
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hol
Guangzhou (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
189 fő, tervezett
Kezdés
2025. máj. 1.
Várható befejezés
2028. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
A vizsgált kezelések
  • repetitive Transcranial Magnetic Stimulation (rTMS)
A regiszteradat frissítve
2026. február 5.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for older adults with age-related hearing loss, with or without hearing aids, and people with normal hearing as a comparison group. The hearing loss groups get rTMS, a magnetic brain stimulation.

Életkor
50 to 85 years
Nem
All sexes
A betegség stádiuma
Age-related hearing loss: slow, similar in both ears, mainly high sounds. The better ear has moderate to severe loss (PTA between 35~79dB). The normal hearing group has PTA ≤25 dB HL in the better ear.
Korábbi kezelés
The hearing aid group must have worn hearing aids for more than half a year, over 7.2 hours a day.

A részvétel fő kizáró okai

  • Hearing loss from noise, genes, ear-damaging drugs or other causes not linked to age
  • Past stroke, epilepsy, brain injury or other brain or nerve system disorder
  • Dementia or other brain-wasting disease
  • Severe body-wide disease, major mental illness or family history of hereditary conditions
  • Cannot have MRI or rTMS

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Age ≥50 years and ≤85 years, regardless of gender
  • Diagnosed with age-related hearing loss (ARHL), characterized by symmetrical, slowly progressing hearing loss primarily affecting high frequencies, along with decreased speech recognition ability due to aging. This is in accordance with the "Expert Consensus on Diagnosis and Intervention of Age-Related Hearing Loss" 2019 edition.(Only ARHL-nonHA group and ARHL-HA group)
  • The better ear has moderate, moderately severe, or severe hearing loss (based on the 2021 WHO hearing classification standards, i.e., PTA between 35~79dB)
  • Wearing hearing aids for more than half a year, with daily wearing time exceeding 7.2 hours; (Only ARHL-HA group)
  • Chinese nationals who can complete all assessments in Chinese
  • Right-handed
  • Educational level of at least 6 years
  • Informed consent obtained, agreeing to participate in the trial with no plans to relocate within one year

Ki nem vehet részt

  • History of central nervous system disorders such as cerebral infarction, stroke, epilepsy, or traumatic brain injury
  • Diagnosis of dementia or other neurodegenerative diseases that affect compliance with the study
  • Presence of major neurological disorders, severe systemic diseases, family history of hereditary conditions, or major psychiatric disorders
  • Exclusion of hearing loss due to noise, genetics, ototoxic drugs, or other non-age-related causes
  • Contraindications to MRI
  • Contraindications to rTMS

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 50 és 85 év között vagy?

Helyszínek itt: Kína

  • Sun Yat Sen Memorial Hospital of Sun Yat sen UniversityGuangzhou, KínaContact: Haidi Yang, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study is a real-world interventional trial enrolling 189 participants: older adults with age-related hearing loss not using hearing aids (ARHL-nonHA), those using hearing aids (ARHL-HA), and those with normal hearing (HC). All groups will undergo hearing, cognitive (MMSE, MoCA, SCWT, DST, TMT), depression (GDS-15, HAMD-24), sleep (PSQI), and brain imaging (EEG, sMRI, rs-fMRI, task-fMRI) assessments. The ARHL-nonHA and ARHL-HA groups will receive two 14-day courses of high-frequency rTMS (one session daily). One month after treatment, reassessments will be conducted in these two groups. Data will then be analyzed to evaluate the cognitive benefits of rTMS combined with hearing aids and to explore the underlying brain mechanisms.

A vizsgálat 3 csoportja

  • ARHL-nonHA groupA vizsgált kezelés

    This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB), meeting the diagnostic criteria outlined in the 2019 expert consensus. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version.

    Kezelés: repetitive Transcranial Magnetic Stimulation (rTMS)

  • ARHL-HA groupA vizsgált kezelés

    This study will use repetitive transcranial magnetic stimulation (rTMS) as an intervention. Participants will be right-handed Chinese individuals aged between 50 and 85 years, diagnosed with moderate to severe age-related hearing loss (pure-tone average PTA of the better ear ranging from 35 to 79 dB).Participants must have been wearing hearing aids for more than six months and use them for over 7.2 hours daily. Eligible participants must have at least 6 years of education and be able to complete all assessments in the Chinese version.

    Kezelés: repetitive Transcranial Magnetic Stimulation (rTMS)

  • HC groupNincs vizsgálati kezelés, összehasonlításként

    Aged between 50 and 85 years, with no gender restriction; pure-tone average (PTA) ≤25 dB HL in the better ear; Chinese nationality, able to complete all Chinese-version assessments; right-handed; and with at least 6 years of education.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Efficacy and Safety of rTMS Combined With HA in the Treatment of Cognitive Decline in Aged Related Hearing Loss: A Single-Center Real-World Study
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07389213: ki vehet részt
A regiszteradat frissítve
2026. február 5.